Share on StockTwits

Mylan (NASDAQ:MYL) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 27,583,008 shares, a decrease of 8.4% from the April 30th total of 30,103,811 shares, Analyst Ratings Network reports. Approximately 7.5% of the company’s stock are sold short. Based on an average daily trading volume, of 4,950,535 shares, the short-interest ratio is currently 5.6 days.

MYL has been the subject of a number of recent research reports. Analysts at Leerink Swann cut their price target on shares of Mylan from $58.00 to $57.00 in a research note on Monday, May 5th. Separately, analysts at RBC Capital cut their price target on shares of Mylan from $62.00 to $60.00 in a research note on Friday, May 2nd. Finally, analysts at Citigroup Inc. upgraded shares of Mylan from a “neutral” rating to a “buy” rating in a research note on Friday, April 4th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $45.27.

Mylan (NASDAQ:MYL) opened at 49.98 on Tuesday. Mylan has a 52 week low of $29.50 and a 52 week high of $57.52. The stock has a 50-day moving average of $48.49 and a 200-day moving average of $47.24. The company has a market cap of $18.679 billion and a P/E ratio of 31.13.

Mylan Inc (NASDAQ:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.